Cigna Group (CI)
Health Care · Health Care Services · US stock · S&P 500 component
$302.30
▲ +3.49 (1.17%)
Fair valueData under review
$823
$411fair band $576–$1,069$1,234
Day's range
$298.23 – $303.08
52-week range
$234.20 – $304.44
About Cigna Group
Cigna Group is a health services company with two main parts: Evernorth, which includes pharmacy benefit management through Express Scripts and specialty care services, and Cigna Healthcare, which sells medical, dental and other insurance plans. Revenue comes from insurance premiums, fees for managing prescription drug benefits and the dispensing of medicines, and it depends on medical costs and regulation.
Over the last twelve months Cigna Group reported revenue of $282.4 billion. Over three years revenue has grown by 15.0% a year. The operating margin is 3.5%. Return on invested capital is 12%. Net debt to EBITDA is 2.0 times. It pays a dividend with a yield of 2.0%. The X-Ray Score is 66 out of 100. Return on invested capital describes how much profit the business earns relative to the money put into it.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $234.20 – $304.44Volume 1,545,500Daily, split-adjusted
Vitals
Market cap$79.8B
52-week range$234.20 – $304.44
Volume (last day)1,545,500
P/E (TTM)12.9
EBIT / EV yield9.4%
Free-cash-flow yield–
Dividend yield2.0%
Revenue (TTM)$282.4B
Net income (TTM)$6.2B
Operating margin3.5%
Return on capital11.8%
Debt incl. leases$32.9B
Cash & securities$7.3B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$823model spread $773 – $880
Data under review
+0.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
Price $302
Undervalued < $576Fair $576 – $1,069Overvalued > $1,069
10-year DCF (market-scaled)
$812
Peer multiples
$730
Earnings power floor (not blended)
$354
Fundamentals-adjusted multiple
$926
Growth the price implies
1.8%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Read the lenses below
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Strong
96/100
Cheap against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield9.4%
Fair value vs price2.7×
Growth
Fair
68/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)15.0%
EPS growth (3y)1.2%
Growth consistency100%
Profitability
Fair
51/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital11.8%
Operating margin3.5%
Gross profitability37.1%
Financial health
Weak
48/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score8 / 9
Net debt / EBITDA2.0×
Interest cover7.2×
Dividends
Fair
63/100
Dividend is typical for its sector.
See the numbers →
Dividend yield2.0%
Dividend growth5.2%
Quarterly results: last 6 quarters
+14.4%
Mar '25
+11.0%
Jun '25
+9.5%
Sep '25
+10.4%
Dec '25
+4.6%
Mar '26
+6.7%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $71.7B, diluted EPS $6.29.
Compare with peers
DVA Davita Inc.66 DGX Quest Diagnostics Inc57 CVS CVS HEALTH Corp52 LH Labcorp Holdings Inc.46Other Health Care Services companies by X-Ray Score.
Fundamentals checklist
● 5 Good · ● 5 Average · ● 4 BadCash quality
Earnings backed by cashBad
Risk models
Altman Z''Bad
Piotroski F-ScoreGood
Growth
EPS growth (3y)Average
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDAAverage
Interest coverAverage
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalAverage
Operating marginBad
Gross profitabilityAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 54/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $174.1B | $180.5B | $195.3B | $247.1B | $274.9B |
| Operating income | $7.9B | $8.5B | $8.5B | $9.4B | $9.2B |
| Net income | $5.4B | $6.8B | $5.2B | $3.4B | $6.0B |
| Operating cash flow | $7.2B | $8.7B | $11.8B | $10.4B | $9.6B |
| Operating margin | 4.6% | 4.7% | 4.4% | 3.8% | 3.3% |
| Free cash flow | – | – | – | – | – |
| Diluted EPS | $15.75 | $21.41 | $17.39 | $12.12 | $22.18 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
12 bullish · 0 neutral · 4 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
6 bullish · 1 neutral · 1 bearish
Moving averages (daily)
| SMA 10 | 284.4 | Bullish |
| EMA 10 | 287.2 | Bullish |
| SMA 20 | 277.8 | Bullish |
| EMA 20 | 282.3 | Bullish |
| SMA 50 | 278.3 | Bullish |
| EMA 50 | 280.0 | Bullish |
| SMA 100 | 281.2 | Bullish |
| EMA 100 | 279.7 | Bullish |
| SMA 200 | 277.9 | Bullish |
| EMA 200 | 280.2 | Bullish |
Oscillators (daily)
| RSI (14) | 73.36 | Bearish |
| MACD (12, 26) | 4.46 | Bullish |
| Momentum (12) | 11.21 | Bullish |
| Stochastic %K (14) | 98.06 | Bearish |
| Williams %R (14) | -1.94 | Bearish |
| CCI (20) | 210.8 | Bearish |
Pivot points (classic, last session)
S3 294.5 | S2 296.4 | S1 299.3 | Pivot 301.2 | R1 304.2 | R2 306.1 | R3 309.0 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
6.19 USD
Yield on today's price
2.05%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 8 Sep 2026 | 1.5600 |
| 4 Jun 2026 | 1.5600 |
| 5 Mar 2026 | 1.5600 |
| 4 Dec 2025 | 1.5100 |
| 4 Sep 2025 | 1.5100 |
| 3 Jun 2025 | 1.5100 |
| 5 Mar 2025 | 1.5100 |
| 4 Dec 2024 | 1.4000 |
| 4 Sep 2024 | 1.4000 |
| 4 Jun 2024 | 1.4000 |
| 5 Mar 2024 | 1.4000 |
| 5 Dec 2023 | 1.2300 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
CI SEC filings
9 Oct 2026
8-KSEC EDGAR
Director or officer change
30 Sep 2026
8-KSEC EDGAR
Regulation FD disclosure
30 Jul 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations
13 May 2026
8-KSEC EDGAR
Regulation FD disclosure
30 Apr 2026
10-QSEC EDGAR
Quarterly report
30 Apr 2026
8-KSEC EDGAR
Results of operations
27 Apr 2026
8-KSEC EDGAR
Shareholder vote results
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.